OptiNose, Inc. (OPTN) Analysts See $-0.75 EPS

July 14, 2018 - By Jeanette Kaplan

Analysts expect OptiNose, Inc. (NASDAQ:OPTN) to report $-0.75 EPS on August, 13.After having $-0.81 EPS previously, OptiNose, Inc.’s analysts see -7.41 % EPS growth. The stock decreased 1.47% or $0.41 during the last trading session, reaching $27.44. About 157,126 shares traded. OptiNose, Inc. (NASDAQ:OPTN) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company has market cap of $1.12 billion. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It currently has negative earnings. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

More notable recent OptiNose, Inc. (NASDAQ:OPTN) news were published by: Nasdaq.com which released: “Optinose CEO Peter Miller and President and COO Ramy Mahmoud Named EY Life Sciences Entrepreneur Of The …” on June 15, 2018, also Globenewswire.com with their article: “Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals” published on June 21, 2018, Streetinsider.com published: “OptiNose’s (OPTN) Xhance Xperience Continues to Gain Momentum – BMO” on July 12, 2018. More interesting news about OptiNose, Inc. (NASDAQ:OPTN) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” published on June 29, 2018 as well as Nasdaq.com‘s news article titled: “Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal” with publication date: July 02, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.